Results 91 to 100 of about 10,632 (179)

Phenotypic impacts of treatment-selected mutations in HIV-2 protease on darunavir and lopinavir susceptibility: Evaluating genotypic HIV-2 drug resistance tools. [PDF]

PLOS Glob Public Health
Raugi DN, Nixon RS, Smith RA, Hawes SE, Diallo K, Diallo MB, Faye K, Diaw B, Sy MP, Sall F, Seydi M, Gottlieb GS, University of Washington-Senegal HIV-2 Study Group.   +12 more
europepmc   +1 more source

Resource Use and Cost Associated With Cardiovascular, Renal, Bone, and Neuropsychiatric Comorbidities in People With HIV in Spain. [PDF]

J Health Econ Outcomes Res
Ventayol P, Dueñas C, Martín C, Castro A, Citoler B, Vidal-Vilar N.   +5 more
europepmc   +1 more source

Highly Potent Phosphinic HIV‑1 Protease Inhibitors: Synthesis, In Vitro Evaluation, and Docking Studies. [PDF]

ACS Omega
Hayat K, Qiu D, Wang Y, Imbenzi PS, Khan FI, Matziari M.   +5 more
europepmc   +1 more source

Mutational scan of self-cleavage by HIV-1 protease provides new views of a conformationally dynamic mechanism. [PDF]

J Virol
Nachum GS, Boucher JI, Flynn JM, Quansah P, Nachum S, Bolon DNA.   +5 more
europepmc   +1 more source

Contemporary antiretroviral pharmacology in the male genital tract: implications for HIV treatment and prevention. [PDF]

Antimicrob Agents Chemother
Neverette NC, Winfield J, Chaparro-Cáceres N, Ho KS, Dumond JB, Devanathan AS.   +5 more
europepmc   +1 more source

2025 US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Post-exposure Prophylaxis in Healthcare Settings. [PDF]

Infect Control Hosp Epidemiol
Kofman AD, Struble KA, Heneine W, Gayle B, de Perio MA, Okasako-Schmucker DL, So CN, Anderson LE, Stone EC, Henderson DK, Kuhar DT.   +10 more
europepmc   +1 more source

Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial. [PDF]

Clin Infect Dis
Obeng BM, Hutchinson J, Shaik A, Chetchotisakd P, Azwa I, Wulan WN, Kumarasamy N, Wolff M, Bruguera J, Losso M, Kaplan R, Diallo MS, Eriobu N, Musoro G, Kumalawati J, Badamasi A, Fitriah M, Mulya DP, Law M, Matthews G, Di Giallonardo F, Kelleher AD, Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D2EFT) Study Group.   +22 more
europepmc   +1 more source

Incident Hypertension with Antiretroviral Therapy in the OPERA Cohort. [PDF]

J Int Assoc Provid AIDS Care
Pierone G, Brunet L, Fusco JS, Lackey PC, Wohlfeiler MB, Dieterich DT, Henegar C, Vannappagari V, Jones B, de Ruiter A, Fusco GP.   +10 more
europepmc   +1 more source

Darunavir analog precursors target mitochondrial metabolism in multiple myeloma and CLL. [PDF]

Cancer Cell Int
Mecca M, Sichetti M, Spina E, Giuseffi M, Giglio E, Picerno S, Valvano L, Statuto T, Santarsiere A, Funicello M, Armentano MF, Chiummiento L, Lupattelli P, Romano A, Giordano A, Cortellino S.   +15 more
europepmc   +1 more source

Effectiveness of simplified ART regimens in older adults living with HIV: real-world evidence from a Brazilian cohort. [PDF]

Braz J Med Biol Res
Stanicki PV, Tasca KI, Zimmerman WR, Barbosa AN.   +3 more
europepmc   +1 more source